Literature DB >> 18568020

The binding sites for cocaine and dopamine in the dopamine transporter overlap.

Thijs Beuming1, Julie Kniazeff, Marianne L Bergmann, Lei Shi, Luis Gracia, Klaudia Raniszewska, Amy Hauck Newman, Jonathan A Javitch, Harel Weinstein, Ulrik Gether, Claus J Loland.   

Abstract

Cocaine is a widely abused substance with psychostimulant effects that are attributed to inhibition of the dopamine transporter (DAT). We present molecular models for DAT binding of cocaine and cocaine analogs constructed from the high-resolution structure of the bacterial transporter homolog LeuT. Our models suggest that the binding site for cocaine and cocaine analogs is deeply buried between transmembrane segments 1, 3, 6 and 8, and overlaps with the binding sites for the substrates dopamine and amphetamine, as well as for benztropine-like DAT inhibitors. We validated our models by detailed mutagenesis and by trapping the radiolabeled cocaine analog [3H]CFT in the transporter, either by cross-linking engineered cysteines or with an engineered Zn2+-binding site that was situated extracellularly to the predicted common binding pocket. Our data demonstrate the molecular basis for the competitive inhibition of dopamine transport by cocaine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568020      PMCID: PMC2692229          DOI: 10.1038/nn.2146

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  45 in total

Review 1.  Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter.

Authors:  F I Carroll; A H Lewin; J W Boja; M J Kuhar
Journal:  J Med Chem       Date:  1992-03-20       Impact factor: 7.446

2.  Cocaine receptors on dopamine transporters are related to self-administration of cocaine.

Authors:  M C Ritz; R J Lamb; S R Goldberg; M J Kuhar
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

3.  Tyrosine 140 of the gamma-aminobutyric acid transporter GAT-1 plays a critical role in neurotransmitter recognition.

Authors:  Y Bismuth; M P Kavanaugh; B I Kanner
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

4.  A putative model of the dopamine transporter.

Authors:  O Edvardsen; S G Dahl
Journal:  Brain Res Mol Brain Res       Date:  1994-12

5.  Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter.

Authors:  E L Barker; K R Moore; F Rakhshan; R D Blakely
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

6.  The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding.

Authors:  J G Chen; A Sachpatzidis; G Rudnick
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

7.  Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid as a third coordinate in the endogenous Zn(2+)-binding site.

Authors:  C J Loland; L Norregaard; U Gether
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

8.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter.

Authors:  B Giros; M Jaber; S R Jones; R M Wightman; M G Caron
Journal:  Nature       Date:  1996-02-15       Impact factor: 49.962

9.  The aqueous accessibility in the external half of transmembrane domain I of the GABA transporter GAT-1 Is modulated by its ligands.

Authors:  Yonggang Zhou; Estelle R Bennett; Baruch I Kanner
Journal:  J Biol Chem       Date:  2004-01-26       Impact factor: 5.157

10.  Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding.

Authors:  S Kitayama; S Shimada; H Xu; L Markham; D M Donovan; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

View more
  176 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

Review 2.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 3.  Substrate and drug binding sites in LeuT.

Authors:  Ajeeta Nyola; Nathan K Karpowich; Juan Zhen; Jennifer Marden; Maarten E Reith; Da-Neng Wang
Journal:  Curr Opin Struct Biol       Date:  2010-06-16       Impact factor: 6.809

4.  Syntaxin 1A regulates dopamine transporter activity, phosphorylation and surface expression.

Authors:  M A Cervinski; J D Foster; R A Vaughan
Journal:  Neuroscience       Date:  2010-07-17       Impact factor: 3.590

5.  Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine.

Authors:  Francesco Napolitano; Alessandra Bonito-Oliva; Mauro Federici; Manolo Carta; Francesco Errico; Salvatore Magara; Giuseppina Martella; Robert Nisticò; Diego Centonze; Antonio Pisani; Howard H Gu; Nicola B Mercuri; Alessandro Usiello
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

6.  Effects of ( R)-Modafinil and Modafinil Analogues on Dopamine Dynamics Assessed by Voltammetry and Microdialysis in the Mouse Nucleus Accumbens Shell.

Authors:  Jacqueline D Keighron; Juliana C Quarterman; Jianjing Cao; Emily M DeMarco; Mark A Coggiano; Apre Gleaves; Rachel D Slack; Claudio Zanettini; Amy Hauck Newman; Gianluigi Tanda
Journal:  ACS Chem Neurosci       Date:  2019-01-31       Impact factor: 4.418

7.  Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.

Authors:  Freja Herborg; Thorvald F Andreassen; Frida Berlin; Claus J Loland; Ulrik Gether
Journal:  J Biol Chem       Date:  2018-03-20       Impact factor: 5.157

Review 8.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

9.  Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands.

Authors:  William C Motel; Jason R Healy; Eddy Viard; Buddy Pouw; Kelly Martin; Rae R Matsumoto; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2013-10-15       Impact factor: 2.823

Review 10.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.